Quantcast

Latest InNexus Biotechnology Inc. Stories

2009-04-20 08:00:00

-- Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries -- DENVER, April 20 /PRNewswire-FirstCall/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL in late stage pre-clinical studies, according to research conducted at InNexus Biotechnology Inc.

2009-04-09 08:00:00

- Additional Presentations Underscore Potency, Binding Capabilities for Antibody Pipeline And Novel Technologies - SCOTTSDALE, Ariz., April 9 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc.

2009-03-25 08:00:00

BRITISH COLUMBIA, Canada, March 25 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology, is pleased to announce that the Company has entered into a loan facility with a group of investors for an aggregate amount of up to USD$2.5 million.

2009-03-06 06:47:00

- Company Receives Allowance of Patent Claims in the U.S. and in India - - InNexus Biotechnology CEO Highlighted in Nature Biotechnology - BRITISH COLUMBIA, Canada, March 6 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc.

2009-03-03 15:01:00

- Agency Supports Company's Production and Clinical and Preclinical Plans for DXL625 - - Live Teleconference Scheduled with Leadership and Scientific Team for March 04, 2009 - BRITISH COLUMBIA, Canada March 3 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc.

2009-01-27 04:31:00

BRITISH COLUMBIA, Canada, Jan. 27 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc.

2008-10-30 09:00:41

BRITISH COLUMBIA, Canada, Oct.

2008-10-28 18:00:28

BRITISH COLUMBIA, Canada, Oct.


Word of the Day
whirret
  • To give a box on the ear to.
The word 'whirret' may be onomatopoeic.